Migraine
64 programs · 64 companies
Programs
64
Companies
64
Trials
58
MOAs
42
GLP-1agCFTRmodCGRPantPI3KiEGFRiBCL-2iUSP1iTROP-2 ADCPD-L1iPARPi
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | NDA/BLA | CD19 | ||
| LLY-4358 | Phase 3 | B7-H3 | ||
| ABB-3060 | Phase 2 | LAG-3 | ||
| Capifutibatinib | Approved | PRMT5 | ||
| GSK-2051 | Phase 1 | PSMA | ||
| Tezecilimab | NDA/BLA | Tau | ||
| AMG-9052 | Phase 2/3 | CDK2 | ||
| GMA-5010 | Phase 3 | JAK2 | ||
| Capifutibatinib | Phase 3 | PCSK9 | ||
| SRP-1135 | Phase 2/3 | MDM2 | ||
| LEG-6533 | NDA/BLA | VEGF | ||
| Olpafutibatinib | Approved | SMN2 | ||
| Zanumavacamten | Phase 2 | FLT3 | ||
| Capicilimab | Phase 1 | EGFR | ||
| SND-9531 | Phase 3 | TYK2 | ||
| Pemisertib | NDA/BLA | VEGF | ||
| Doxacagene | Phase 1/2 | C5 | ||
| 187-151 | Phase 1 | Aβ | ||
| UCL-IIT-280 | Preclinical | AuroraA | ||
| Zoribrutinib | Phase 1/2 | DLL3 | ||
| TES-8949 | Phase 3 | AuroraA | ||
| Adagralemzoparlimab | Approved | HER2 | ||
| GRT-6331 | NDA/BLA | TROP-2 | ||
| Fixainavolisib | Phase 2/3 | APOC3 | ||
| Rimabrutinib | Preclinical | FXIa | ||
| Voxazanubrutinib | Phase 1/2 | PCSK9 | ||
| ZYN-3484 | Phase 2/3 | CFTR | ||
| Polatenlimab | NDA/BLA | DLL3 | ||
| Elrasotorasib | NDA/BLA | WRN | ||
| Tezerapivir | Preclinical | Menin | ||
| PBL-8716 | Preclinical | GLP-1R | ||
| Tezezasiran | Phase 2 | PRMT5 | ||
| NUW-823 | Phase 1 | SGLT2 | ||
| Gelizasiran | Phase 3 | RET | ||
| CHI-1577 | Phase 2/3 | HER2 | ||
| ABB-879 | Phase 1 | WEE1 | ||
| Pemiratamab | Phase 2 | ALK | ||
| Darasertib | Phase 1/2 | AHR | ||
| BIG-7200 | Phase 1 | KRASG12D | ||
| HAR-6503 | Approved | CDK2 | ||
| FDM-9341 | Phase 2/3 | JAK1 | ||
| STA-IIT-276 | Phase 3 | JAK1 | ||
| Voxafutibatinib | Phase 1 | TYK2 | ||
| Talafotisoran | NDA/BLA | PSMA | ||
| Adagraderotide | Phase 2 | CD20 | ||
| Zenovorutinib | Phase 2 | GPRC5D | ||
| Tixaratamab | Preclinical | Tau | ||
| PPL-6055 | Phase 2/3 | Nectin-4 | ||
| Pexatinib | Phase 3 | EGFR | ||
| PHO-7143 | Phase 2/3 | PD-L1 | ||
| OGN-5336 | Phase 1 | IL-13 | ||
| POL-5703 | Approved | EZH2 | ||
| ALK-3993 | Phase 3 | SOS1 | ||
| Semafotisoran | Phase 1 | KRASG12C | ||
| BIO-9702 | Phase 1 | SOS1 | ||
| ABD-3507 | Preclinical | VEGF | ||
| ASP-8946 | Phase 1 | MET | ||
| Tixasotorasib | Preclinical | PSMA | ||
| EGI-5078 | Phase 2 | FGFR | ||
| Darasertib | Phase 1 | Nectin-4 | ||
| Fixatinib | Phase 1/2 | IL-17A | ||
| Fixatenlimab | NDA/BLA | MALT1 | ||
| Sovalemzoparlimab | Phase 3 | GPRC5D | ||
| Teraosocimab | Phase 3 | CDK4/6 |
Trials (58)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT05636754 | LLY-4358 | Phase 3 | Not yet recr... |
| NCT05023327 | LLY-4358 | Phase 3 | Terminated |
| NCT04495524 | ABB-3060 | Phase 2 | Completed |
| NCT03250318 | ABB-3060 | Phase 2 | Recruiting |
| NCT03829309 | Capifutibatinib | Approved | Completed |
| NCT03215766 | Capifutibatinib | Approved | Completed |
| NCT04645038 | Capifutibatinib | Approved | Not yet recr... |
| NCT07702964 | GSK-2051 | Phase 1 | Not yet recr... |
| NCT08174683 | Capifutibatinib | Phase 3 | Not yet recr... |
| NCT03698315 | SRP-1135 | Phase 2/3 | Not yet recr... |
| NCT07675662 | LEG-6533 | NDA/BLA | Not yet recr... |
| NCT07722426 | LEG-6533 | NDA/BLA | Recruiting |
| NCT06053301 | Olpafutibatinib | Approved | Completed |
| NCT07306383 | Olpafutibatinib | Approved | Recruiting |
| NCT08105941 | Capicilimab | Phase 1 | Completed |
| NCT06384213 | SND-9531 | Phase 3 | Terminated |
| NCT04643503 | 187-151 | Phase 1 | Recruiting |
| NCT07636880 | UCL-IIT-280 | Preclinical | Recruiting |
| NCT05510816 | TES-8949 | Phase 3 | Active |
| NCT05172333 | Adagralemzoparlimab | Approved | Terminated |